Biotech Business - October 2, 2023
New company aims to redefine cell therapy development
Alder Therapeutics is a newly founded preclinical phase stem cell therapy development company with the goal to reshape the cell therapy sector with a novel, reduced-risk approach and two cell therapy candidates for diseases with high unmet need. Alder Therapeutics was formed in 2022 to unlock the benefits of PSCs for patients across the world, […]
New Market - September 19, 2023
Orexo submits New Drug Application to FDA
Orexo has announced the submission of the New Drug Application (NDA) to the US Food and Drug Administration for OX124, a high-dose rescue medication for opioid overdose with nasal delivery. OX124, is based on Orexo’s drug delivery platform amorphOX and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl. […]
MedTech Business - September 6, 2023
Devyser and Thermo Fisher Scientific expand collaboration
Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including Brazil in the exclusive collaboration and distribution agreement for Devyser’s post-transplant portfolio of NGS products. In addition to North America and Europe, Thermo Fisher will now exclusively market and sell Devyser’s transplantation products under combined brands also in Brazil. “We are very […]
MedTech Business - September 6, 2023
Senzime receives its largest US order to date
Senzime has announces an initial order from a California-based hospital system. The order consists of 110 TetraGraph monitors as well as consumables and is the result of a comprehensive clinical and competitive product evaluation. “This is another fantastic milestone for Senzime and our largest US order to date from one of the greatest hospital systems […]
New Market - September 4, 2023
AstraZeneca’s Calquence approved in China
Calquence, a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in China for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy. “Today’s approval is another step towards our goal of making Calquence available to as many patients […]
MedTech Business - August 23, 2023
Episurf’s first commercial case in the US scheduled
Episurf Medical has announced that the company’s first commercial case in the US has been scheduled for surgery. This is also the first case ever with the newly introduced product Episealer Patellofemoral System, states the company. The product is a fully individualized implant system for patients with isolated osteoarthritis of the patellofemoral joint in the […]
